Georgia's Online Cancer Information Center

Non-Hodgkin Lymphoma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Non-Hodgkin Lymphoma
Cancer Type = Non-Hodgkin Lymphoma
There are currently 53 active Non-Hodgkin Lymphoma clinical trials in Georgia.
1.
9-ING-41 in Patients With Advanced Cancers
Cancer Type
Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT03678883
Protocol IDs
1801
NCI-2018-03166
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04115631
Protocol IDs
EA4181
NCI-2019-05536
EA4181
Treatment Sites (2)
3.
NCORP Trial
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCT ID
NCT00078598
Protocol IDs
CCBX001-049
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
7.
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT04035434
Protocol IDs
CRSP-ONC-001
NCI-2019-07066
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04712097
Protocol IDs
GO42909
NCI-2021-09247
2020-005239-53
9.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03571568
Protocol IDs
17-BI1206-02
NCI-2018-02697
Treatment Sites (1)
10.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
11.
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT03740529
Protocol IDs
LOXO-BTK-18001
NCI-2019-02015
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Leukemia, Neuroblastoma, Non-Hodgkin Lymphoma
NCT ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
13.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
14.
Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant
Cancer Type
Non-Hodgkin Lymphoma
NCT ID
NCT03114865
Protocol IDs
J1713
NCI-2019-00402
CRMS-65830
IRB00125679
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
15.
Childhood Cancer Survivor Study
Cancer Type
Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Solid Tumor
NCT ID
NCT01120353
Protocol IDs
CCSS
U24CA055727
Treatment Sites (2)
16.
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Cancer Type
Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT03904134
Protocol IDs
BMT CTN 1702
NCI-2019-03477
N00014-18-1-2888
5U24HL138660-02
17.
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04890236
Protocol IDs
Winship5085-20
NCI-2020-06380
STUDY00001001
18.
Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Wilms Tumor
NCT ID
NCT03213652
Protocol IDs
APEC1621F
APEC1621F
APEC1621F
NCI-2017-01243
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
19.
Erdafitinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with FGFR Mutations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03210714
Protocol IDs
APEC1621B
APEC1621B
NCI-2017-01159
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
20.
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type
Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT03501576
Protocol IDs
Winship4236-17
NCI-2017-02313
IRB00101067
Treatment Sites (2)
21.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
22.
Ibrutinib and Pembrolizumab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03153202
Protocol IDs
17-0554
NCI-2017-01538
23.
NCORP Trial
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02443077
Protocol IDs
A051301
NCI-2015-00668
BMT CTN 1201
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
24.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
25.
Ivosidenib in Treating Patients with Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with IDH1 Mutations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT04195555
Protocol IDs
APEC1621K
APEC1621K
NCI-2019-08098
26.
Larotrectinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with NTRK Fusions (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03213704
Protocol IDs
APEC1621A
APEC1621A
NCI-2017-01264
APEC1621A
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
27.
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCT ID
NCT02568553
Protocol IDs
9924
9924
NCI-2015-01640
PHI-79
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
28.
Maintenance Obinutuzumab in Treating Patients with Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02498951
Protocol IDs
IRB00011601
NCI-2015-01014
ML29496
29.
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04676087
Protocol IDs
WINSHIP5101-20
NCI-2020-06013
30.
Nivolumab and Lenalidomide in Treating Patients with Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT03015896
Protocol IDs
OSU-16167
NCI-2016-01966
2016C0166
Treatment Sites (1)
31.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
32.
Nivolumab with or without Varlilumab in Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03038672
Protocol IDs
10089
10089
NCI-2017-00120
MC168D
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
33.
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT04136756
Protocol IDs
18-255-02
NCI-2019-07642
34.
NCORP Trial
Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03269669
Protocol IDs
S1608
S1608
NCI-2017-00009
S1608
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
35.
Palbociclib in Treating Patients with Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma
NCT ID
NCT03526250
Protocol IDs
APEC1621I
APEC1621I
NCI-2018-00863
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
36.
Pembrolizumab and Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03598998
Protocol IDs
17501
NCI-2018-01420
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
37.
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04665765
Protocol IDs
20148
NCI-2020-08524
38.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03267433
Protocol IDs
EA4151
EA4151
NCI-2016-01403
EA4151
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
39.
Samotolisib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03213678
Protocol IDs
APEC1621D
APEC1621D
APEC1621D
NCI-2017-01249
Treatment Sites (1)
40.
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders with Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT04320888
Protocol IDs
APEC1621N
APEC1621N
NCI-2020-01756
Treatment Sites (1)
41.
NCORP Trial
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02631044
Protocol IDs
017001
NCI-2016-00057
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
42.
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
43.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT04756726
Protocol IDs
CFT7455-1101
NCI-2021-05587
44.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
45.
NCORP Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCT ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
Treatment Sites (3)
46.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
Treatment Sites (1)
47.
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03984448
Protocol IDs
A051701
A051701
NCI-2019-03711
Treatment Sites (2)
48.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
49.
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Cancer Type
Brain & Spinal Cord Tumor, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Thyroid Cancer
NCT ID
NCT04284774
Protocol IDs
APEC1621M
APEC1621M
NCI-2020-01015
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
50.
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02495415
Protocol IDs
FEN T-14
NCI-2015-01195
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
52.
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT03786926
Protocol IDs
2018-689-US001
NCI-2019-01158
2018-689-00US1
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
53.
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04703192
Protocol IDs
DS3201-A-U202
2020-004954-31
NCI-2021-06342
jRCT2071200095
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.